#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Transient ischaemic attack Diffuse large B-cell lymphoma recurrent Penile cancer Alagille syndrome Liposarcoma Neuromyelitis optica spectrum disorder Langerhans cell sarcoma Neuroblastoma Leiomyosarcoma White matter lesion Isodicentric chromosome 15 syndrome ABO haemolytic disease of newborn Progressive multifocal leukoencephalopathy Toxic epidermal necrolysis Dupuytren's contracture More trials…

    Learn about Rare Diseases

    Haemophilia Mucopolysaccharidosis III Rhabdomyosarcoma Ehlers-Danlos syndrome – Trials in Disease Marginal zone lymphoma – Basic Information Splenic marginal zone lymphoma – Life with Disease Lysosomal storage disorder – Life with Disease Pulmonary sarcoidosis Encephalitis autoimmune – Treatment Atypical haemolytic uraemic syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Atidarsagene Autotemcel Estradiol Valerate Desoximetasone Oms906 Melphalan MARALIXIBAT Ecoo16 Eptacog Alfa (Activated) Reparixin GRAPHITE Mbf-118 Sisunatovir Candesartan FOSFOMYCIN CALCIUM Vib1116 Bomedemstat Leniolisib Phosphate Benzalkonium Chloride BIIB115 Vinflunine More therapies…

    Learn about Your Condition

    Altered state of consciousness Glioma Breast neoplasm Peripheral spondyloarthritis Skin candida Chordoma Lymphangiosarcoma Muscle spasticity Urinary tract infection Pericarditis Immunodeficiency congenital Myeloid leukaemia Langerhans cell sarcoma Diarrhoea Pulmonary tuberculosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Retinitis pigmentosa

  • Study of GS030 gene therapy safety and tolerability in patients with Retinitis Pigmentosa

    Recruiting

    1 1 1
    Investigated Diseases:
    • Retinitis pigmentosa
    Investigated Drugs:
    • Adeno-Associated Viral Vector Serotype 2.7M8 Containing The Chrimsonr-Tdtomato Gene
    France

  • Study on the Safety and Effects of ISTEM-01 and Mycophenolate Mofetil for Patients with Retinitis Pigmentosa Due to a Genetic Mutation

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Retinitis pigmentosa
    Investigated Drugs:
    • Istem-01
    • Mycophenolate Mofetil
    France

  • Study on the Effectiveness and Safety of Ultevursen for Patients with Retinitis Pigmentosa Due to USH2A Gene Mutations

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Retinitis pigmentosa
    Investigated Drugs:
    • ULTEVURSEN
    France Germany Italy The Netherlands

  • Study on the Safety and Effectiveness of AGTC-501 for Men with X-linked Retinitis Pigmentosa

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Retinitis pigmentosa
    Investigated Drugs:
    • Adeno-Associated Virus Vector Containing The Human Rpgr Gene
    • Brinzolamide
    • Dorzolamide
    Spain

  • Study of ultevursen treatment in patients with retinitis pigmentosa caused by mutations in USH2A gene exon 13

    Not recruiting

    2 1
    Investigated Diseases:
    • Retinitis pigmentosa
    Investigated Drugs:
    • ULTEVURSEN
    Belgium Denmark France Germany Italy The Netherlands

  • Long-term Safety and Efficacy Study of Gene Therapy for Choroideremia and X-Linked Retinitis Pigmentosa Using AAV2-REP1 and AAV8-RPGR in Previously Treated Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Choroidal dystrophy
    • Retinitis pigmentosa
    Investigated Drugs:
    • Timrepigene Emparvovec
    France Germany
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!